ConductScience.org, home

Paper41006418

Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma.

Morshed MN and 8 others. Sci Rep, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma. Papers, record 41006418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41006418

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of novel small molecule inhibitors targeting multiple methyltransferase like proteins against hepatocellular carcinoma.
PubMed
Journal
Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.51, provisional
iCite
Revised in PubMed
2025-09-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Morshed MNMd Niaz
2Parvez SASorwer Alam
3Akanda RIRakibul Islam
4Saha MKManash Kumar
5Fardous JJannatul
6Alam MMaksudul
7Zhao YYunfeng
8Franco OEOmar E
9Hosen MJMohammad Jakir

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
MethyltransferasesMajor topic
Enzyme InhibitorsMajor topic
Antineoplastic AgentsMajor topic
Small Molecule LibrariesMajor topic
Humans
Cell Proliferation
Cell Line, Tumor
Hep G2 Cells
Molecular Dynamics Simulation

Source PubMed

Download CSV of topics

References71

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135961526Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy.Cell Signal2022https://conductscience.org/library/papers/35961526PubMed
235784404Novel roles of METTL1/WDR4 in tumor via m7G methylation.Mol Ther Oncolytics2022https://conductscience.org/library/papers/35784404PubMed
334285249Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer.Sci Rep2021https://conductscience.org/library/papers/34285249PubMed
435429902TSPAN31 regulates the proliferation, migration, and apoptosis of gastric cancer cells through the METTL1/CCT2 pathway.Transl Oncol2022https://conductscience.org/library/papers/35429902PubMed
5344316641,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.J Med Chem2021https://conductscience.org/library/papers/34431664PubMed
632834109DFT studies on vibrational and electronic spectra, HOMO-LUMO, MEP, HOMA, NBO and molecular docking analysis of benzyl-3-N-(2,4,5-trimethoxyphenylmethylene)hydrazinecarbodithioate.J Mol Struct2020https://conductscience.org/library/papers/32834109PubMed
722553363ZINCPharmer: pharmacophore search of the ZINC database.Nucleic Acids Res2012https://conductscience.org/library/papers/22553363PubMed
831463732METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN.J Mol Med (Berl)2019https://conductscience.org/library/papers/31463732PubMed
917016424Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.Nat Rev Drug Discov2006https://conductscience.org/library/papers/17016424PubMed
1034452630DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application.Clin Epigenetics2021https://conductscience.org/library/papers/34452630PubMed
1134790902Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.Nat Cancer2021https://conductscience.org/library/papers/34790902PubMed
1234623518Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications.J Cancer Res Clin Oncol2022https://conductscience.org/library/papers/34623518PubMed
1333151290PubChem in 2021: new data content and improved web interfaces.Nucleic Acids Res2021https://conductscience.org/library/papers/33151290PubMed
1432508653Discovering Anti-Cancer Drugs via Computational Methods.Front Pharmacol2020https://conductscience.org/library/papers/32508653PubMed
1532068977METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma.Cancer Med2020https://conductscience.org/library/papers/32068977PubMed
1616578791Absolute electronegativity and hardness correlated with molecular orbital theory.Proc Natl Acad Sci U S A1986https://conductscience.org/library/papers/16578791PubMed
1718424800PharmaGist: a webserver for ligand-based pharmacophore detection.Nucleic Acids Res2008https://conductscience.org/library/papers/18424800PubMed
1836408920UniProt: the Universal Protein Knowledgebase in 2023.Nucleic Acids Res2023https://conductscience.org/library/papers/36408920PubMed
1933902106Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.Nature2021https://conductscience.org/library/papers/33902106PubMed
2035158892Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances.Cancers (Basel)2022https://conductscience.org/library/papers/35158892PubMed

See all 71 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42162629N6-methyladenosine modification in the context of viral infection: from molecular mechanism to therapeutic potential.Virus Res2026https://conductscience.org/library/papers/42162629PubMed
41952207METTL16 promotes MASLD progression through the regulation of lipid synthesis and immune response.Biol Direct2026https://conductscience.org/library/papers/41952207PubMed
41938016Recent advances in m6A RNA modification in hepatocellular carcinoma: from mechanisms to therapeutic potential.Front Mol Biosci2026https://conductscience.org/library/papers/41938016PubMed
41852637The Future of Epigenetics: Emerging Technologies and Clinical Applications.ACS Pharmacol Transl Sci2026https://conductscience.org/library/papers/41852637PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
METTL14234PubTator's text mininghttps://conductscience.org/library/genes/4234NCBI Gene
METTL1679066PubTator's text mininghttps://conductscience.org/library/genes/79066NCBI Gene
METTL1892342PubTator's text mininghttps://conductscience.org/library/genes/92342NCBI Gene
METTL356339PubTator's text mininghttps://conductscience.org/library/genes/56339NCBI Gene
METTL6131965PubTator's text mininghttps://conductscience.org/library/genes/131965NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41006418

GET https://conductscience.org/api/papers/v1/41006418/references?page=2